Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J McIntyre

Showing results (401-410 of 438) with videos related to

Pageof 44
Sort By:
Bioorganic & Medicinal Chemistry Letters|August 23, 2015
7-(Pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine-based derivatives for kinase inhibition: Co-crystallisation studies with Aurora-A reveal distinct differences in the orientation of the pyrazole N1-substituentVassilios Bavetsias, Yolanda Pérez-Fuertes, Patrick J McIntyre, et al.
Dalton Transactions (Cambridge, England : 2003)|October 10, 2012
Scrutinizing negative thermal expansion in MOF-5 by scattering techniques and ab initio calculationsNina Lock, Mogens Christensen, Yue Wu, et al.
Acta Oncologica (Stockholm, Sweden)|October 24, 2001
Issues of normal tissue toxicity in patient and animal studies--effect of carbogen breathing in rats after 5-fluorouracil treatmentJ R Griffiths, D J McIntyre, F A Howe, et al.
ACS Chemical Biology|October 19, 2017
Characterization of Three Druggable Hot-Spots in the Aurora-A/TPX2 Interaction Using Biochemical, Biophysical, and Fragment-Based ApproachesPatrick J McIntyre, Patrick M Collins, Lukáš Vrzal, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 1, 1997
Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongationJ J Cook, G R Sitko, M A Holahan, et al.
BMC Research Notes|December 6, 2013
Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signalingFrankie Ann Holmes, Virginia Espina, Lance A Liotta, et al.
Scientific Reports|June 24, 2017
Understanding the Unusual Response to High Pressure in KBe<sub>2</sub>BO<sub>3</sub>F<sub>2</sub>D H Yu, M Avdeev, D H Sun, et al.
AIDS Care|May 18, 2010
Prioritising prevention strategies for patients in antiretroviral treatment programmes in resource-limited settingsA Spaar, C Graber, F Dabis, et al.
Antimicrobial Agents and Chemotherapy|October 21, 2009
MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A proteaseNigel J Liverton, Steven S Carroll, Jillian Dimuzio, et al.
Cancer Medicine|March 28, 2018
Five-year results of a phase II trial of preoperative 5-fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (wTX) (with trastuzumab in HER2-positive patients) for patients with stage II or III breast cancerFrankie Ann Holmes, Beth A Hellerstedt, John E Pippen, et al.
Pageof 44

Showing results (401-410 of 438) with videos related to

Sort By:
Pageof 44
Bioorganic & Medicinal Chemistry Letters|August 23, 2015
7-(Pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine-based derivatives for kinase inhibition: Co-crystallisation studies with Aurora-A reveal distinct differences in the orientation of the pyrazole N1-substituentVassilios Bavetsias, Yolanda Pérez-Fuertes, Patrick J McIntyre, et al.
Dalton Transactions (Cambridge, England : 2003)|October 10, 2012
Scrutinizing negative thermal expansion in MOF-5 by scattering techniques and ab initio calculationsNina Lock, Mogens Christensen, Yue Wu, et al.
Acta Oncologica (Stockholm, Sweden)|October 24, 2001
Issues of normal tissue toxicity in patient and animal studies--effect of carbogen breathing in rats after 5-fluorouracil treatmentJ R Griffiths, D J McIntyre, F A Howe, et al.
ACS Chemical Biology|October 19, 2017
Characterization of Three Druggable Hot-Spots in the Aurora-A/TPX2 Interaction Using Biochemical, Biophysical, and Fragment-Based ApproachesPatrick J McIntyre, Patrick M Collins, Lukáš Vrzal, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 1, 1997
Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongationJ J Cook, G R Sitko, M A Holahan, et al.
BMC Research Notes|December 6, 2013
Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signalingFrankie Ann Holmes, Virginia Espina, Lance A Liotta, et al.
Scientific Reports|June 24, 2017
Understanding the Unusual Response to High Pressure in KBe<sub>2</sub>BO<sub>3</sub>F<sub>2</sub>D H Yu, M Avdeev, D H Sun, et al.
AIDS Care|May 18, 2010
Prioritising prevention strategies for patients in antiretroviral treatment programmes in resource-limited settingsA Spaar, C Graber, F Dabis, et al.
Antimicrobial Agents and Chemotherapy|October 21, 2009
MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A proteaseNigel J Liverton, Steven S Carroll, Jillian Dimuzio, et al.
Cancer Medicine|March 28, 2018
Five-year results of a phase II trial of preoperative 5-fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (wTX) (with trastuzumab in HER2-positive patients) for patients with stage II or III breast cancerFrankie Ann Holmes, Beth A Hellerstedt, John E Pippen, et al.
Pageof 44